Stocrin

Riik: Austraalia

keel: inglise

Allikas: Department of Health (Therapeutic Goods Administration)

Toimeaine:

Efavirenz

Saadav alates:

Merck Sharp & Dohme Australia Pty Ltd

Klass:

Medicine Listed (Export Only)

Infovoldik

STOCRIN
®

_Efavirenz_
CONSUMER MEDICINE INFORMATION

WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about STOCRIN. It does
not contain all the available
information.
It does not take the place of talking to
your doctor or pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you taking STOCRIN
against the benefits they expect it
will have for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR, PHARMACIST OR TREATMENTS
OFFICER AT YOUR LOCAL AIDS COUNCIL.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT STOCRIN IS
USED FOR
STOCRIN is used to help treat HIV
(Human Immunodeficiency Virus)
infection. It is used in combination
with other appropriate medicines
used to treat the HIV virus. Examples
include protease inhibitors such as
indinavir (Crixivan*) and nelfinavir
(Viracept*). They also include
nucleoside analogue reverse
transcriptase inhibitors (NRTIs) such
as zidovudine (AZT, Retrovir*) or
lamivudine (3TC).
STOCRIN belongs to a group of
medicines called non-nucleoside
reverse transcriptase inhibitors
(NNRTIs). It works by interrupting
the formation of new HIV particles in
already infected cells. When HIV is
attacked by STOCRIN, the virus is
not able to reproduce normally. This
helps reduce the amount of virus in
the blood. Although STOCRIN helps
reduce the amount of virus in the
blood and thus increases the CD4
count, it has not yet been shown to
improve survival or slow the
progression of the disease.
You may continue to develop
infections or other illnesses
associated with HIV disease while
you are taking STOCRIN.
BEFORE YOU TAKE
STOCRIN
_WHEN YOU MUST NOT TAKE IT_
DO NOT TAKE STOCRIN IF:
•
YOU HAVE AN ALLERGY TO
STOCRIN OR ANY OF THE
INGREDIENTS LISTED AT THE END OF
THIS LEAFLET
•
THE PACKAGING IS TORN OR SHOWS
SIGNS OF TAMPERING
•
THE EXPIRY DATE ON THE PACK HAS
PASSED.
 If you take this medicine after the
expiry date has passed, it may not
work.
•
YOU ARE BREAST FEEDING OR PLAN
TO BR

Toote omadused

WPC-MK0831-MF-032012 

1 
PRODUCT INFORMATION 

STOCRIN
®

(EFAVIRENZ) 

TABLETS, CAPSULES AND ORAL SOLUTION 

NAME OF THE DRUG 

Efavirenz 

DESCRIPTION 

STOCRIN
*
 is a
non-nucleoside reverse transcriptase inhibitor of human immunodeficiency 
virus type 1 (HIV-1). 

Efavirenz is chemically described
as (S) -6- chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-
(trifluoromethyl)-2H-3,1-benzoxazin-2-one. 

Its empirical formula is C
14
H
9
ClF
3
NO
2
 and its structural formula is: 

O
N
O
Cl
H
F
3
C

CAS Registry Number: 154598-52-4 

Efavirenz is a white to slightly pink crystalline powder with
a molecular mass of 315.68.  It is 
practically insoluble in water (<10 

g/mL). 

STOCRIN

 is available as tablets and capsules
for oral administration.  Each STOCRIN 
capsule contains 50, 100 or 200 mg and each
STOCRIN tablet contains 50, 200, 300 or 600 
mg of efavirenz. STOCRIN is also available as an oral solution
containing 30 mg efavirenz 
per mL. 

Each capsule also contains the inactive
ingredients sodium lauryl sulfate, lactose, 
magnesium stearate, and sodium starch glycollate.  The capsule
shell contains the following 
inactive ingredients and
dyes: gelatin, sodium lauryl sulfate, titanium dioxide and/or yellow 
iron oxide.  The capsule shells may also contain
silicon dioxide.  The capsules are printed 
with ink containing indigo carmine CI73015 and titanium dioxide. 

Each tablet contains the following inactive
ingredients: croscarmellose sodium, cellulose - 
microcrystalline, sodium lauryl sulfate, hydroxypropylcellulose, lactose and
magnesium 
stearate.  The film coating contains the following inactive
ingredients and dyes: 

®
Registered Trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., W